1-(1-金刚烷)哌嗪 | 19984-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(1-金刚烷)哌嗪
• 英文名称: N-(1-Adamantyl)-piperazin
• 英文别名: 1-(1-Adamantyl)piperazine
• CAS: 19984-46-4
• 化学式: C₁₄H₂₄N₂
• mdl: MFCD01748381
• 分子量: 220.358
• InChiKey: DXYGTOJPNHDXRM-UHFFFAOYSA-N

物化性质

• 熔点：
  83-85 °C (sublm)
• 沸点：
  312.0±10.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933599090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-(1-Adamantyl)Piperazine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 220,36 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-(1-Adamantyl)Piperazine
<= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-(1-Adamantyl)Piperazine
Xn, R22 <= 100 %

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-(1-金刚烷)哌嗪 在 盐酸 、 sodium hydroxide 、 sodium nitrite 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 0.33h， 生成 bis(4-(adamantyl)-1-piperazinylthiocarbonyl) disulfide
  参考文献：
  名称：

  二硫键在双（二烷基胺硫代羰基）二硫作为有效的双刃杀微生物杀精子剂中的作用：设计，合成和生物学

  摘要：

  滴虫病和念珠菌病是最常见的致病性生殖道感染，通常分别用甲硝唑和氟康唑治疗。阴道功效差，耐药性和非杀精性限制了它们作为局部杀微生物避孕药的使用。双（二烷基胺硫代羰基）二硫化物（4 – 38）被设计为具有双重活性的非表面活性剂分子，能够消除阴道毛滴虫和念珠菌菌株，并且能够以不可细胞毒性的剂量立即不可逆地固定100％人类精子，对人类宫颈上皮细胞和体外阴道菌群。化合物12，16，17它们的活性是非氧化酚9，OTC阴道杀精子剂的50倍，并且化合物12和17在兔模型中显示出显着的体内活性。最有前途的化合物17由于具有更高的活性和安全性以及显着的体内滴虫杀菌活性，已显示出有望进一步发展为双刃阴道杀微生物剂。二硫化物基团的作用是由于化学修饰过程中杀精子活性的丧失而确立的（39 – 56）。这些二硫化物可能靶向存在于人精子和滴虫的细胞膜上的巯基，如游离巯基的荧光标记所示。

  DOI：

  10.1016/j.ejmech.2016.03.012
• 作为产物：
  描述：

  3-[2-(1-adamantylamino)ethyl]-1,3-oxazolidin-2-one 在 氢溴酸 作用下， 生成 1-(1-金刚烷)哌嗪
  参考文献：
  名称：

  使用2-恶唑烷酮作为潜在的氮丙啶等效物。三，N-取代的哌嗪的制备

  摘要：

  由各种取代的2-恶唑烷酮衍生物3制备了许多N-芳基和N-烷基取代的哌嗪1。该方法包括在冰醋酸中用HBr处理3，然后在醇溶剂中加热所得的开环盐5。通过结晶分离出哌嗪1a-1q，产率为23-91％。

  DOI：

  10.1016/0040-4039(94)85306-1

文献信息

• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Link T. James

  公开号：US20050277647A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC)
  作者：Wentian Wang、Lu Zhang、Lorraine Morlock、Noelle S. Williams、Jerry W. Shay、Jef K. De Brabander

  DOI：10.1021/acs.jmedchem.9b00532

  日期：2019.5.23

  small-molecule-based therapies available that specifically target colorectal cancer (CRC) development and progression, the second leading cause of cancer deaths. We previously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (TASIN-1), a small molecule that specifically targets colorectal cancer cells lines with truncating mutations in the adenomatous polyposis

  尽管靶向抗癌疗法取得了进展，但仍没有针对小分子结肠直肠癌（CRC）发育和进程的小分子疗法，这是导致癌症死亡的第二大原因。我们先前披露了截短性腺瘤性结肠炎（APC）选择性抑制剂1（TASIN-1）的发现，这是一种小分子，可通过抑制腺瘤性息肉病（APC）肿瘤抑制基因中的截短突变而特异性靶向结直肠癌细胞系胆固醇的生物合成。在这里，我们报告了TASIN类似物的集合及其对结肠癌细胞系和等基因细胞系对活性的报告，报告了APC依赖选择性的状态。鉴定出许多有效的和选择性的类似物，包括具有良好代谢稳定性和药代动力学特性的化合物。本文报道的化合物代表了首个基因型选择性系列，该系列特异性靶向大多数CRC患者中存在的apc突变，并充当结肠癌靶向治疗的翻译平台。
• Piperazine and homopiperazine derivatives, pharmaceutical compositions
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05380724A1

  公开（公告）日：1995-01-10

  This invention relates to novel compounds of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof. In the general formula (I) ##STR1## wherein Lip, A.sup.1, A.sup.2, Het and n are defined as in the specification. The compounds of the general formula (I) inhibit the lipid peroxidation and therefore, they are useful for the treatment or prevention of diseases and conditions wherein the inhibition of lipid peroxidation is desirable.

  本发明涉及具有通式(I)的新颖化合物及其药学上可接受的酸加成盐。在通式(I)中，其中Lip、A1、A2、Het和n如说明书中所定义。通式(I)的化合物抑制脂质过氧化，因此，它们可用于治疗或预防需要抑制脂质过氧化的疾病和状况。
• [EN] THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLANT LA POLYPOSE ADÉNOMATEUSE COLIQUE (APC) MUTANTE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV TEXAS

  公开号：WO2020117972A1

  公开（公告）日：2020-06-11

  The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and without truncating APC-mutations, as well as in an isogenic cell line pair reporting on the status of APC- dependent selectivity. A number of very potent and selective compounds were identified, including compounds with good metabolic stability and PK properties. The small molecules reported herein thus represent a first-in-class genotype-selective series that specifically target ape mutations present in the vast majority of CRC patients, and therefore serves as a translational platform towards a potential targeted therapy for colon cancer.

  本披露报告了对大量截断APC-选择性抑制剂（TASIN）化合物的广泛药物化学评估。这些化合物针对一系列结肠癌细胞系进行了活性评估，包括具有截断APC突变和不具有截断APC突变的细胞系，以及在报告APC依赖性选择性状况的同源细胞系对。鉴定了一些非常有效和选择性的化合物，包括具有良好代谢稳定性和药代动力学性质的化合物。因此，本文报道的小分子代表了一种首创的基因型选择性系列，专门针对存在于绝大多数结直肠癌患者中的猿类突变，因此可作为一个转化平台，朝着结肠癌的潜在靶向治疗迈进。
• Synthesis and Biological Evaluation of Amidinourea Derivatives against Herpes Simplex Viruses
  作者：Anita Toscani、Rossana Denaro、Sergio Fernando Castillo Pacheco、Matteo Biolatti、Silvia Anselmi、Valentina Dell’Oste、Daniele Castagnolo

  DOI：10.3390/molecules26164927

  日期：——

  on the use of a few nucleoside antivirals such as acyclovir, famciclovir and valacyclovir. However, the current drugs are ineffective against latent and drug-resistant HSV infections. A series of amidinourea compounds, designed as analogues of the antiviral drug moroxydine, has been synthesized and evaluated as potential non-nucleoside anti-HSV agents. Three compounds showed micromolar activity against

  目前针对单纯疱疹病毒 (HSV) 的治疗依赖于使用一些核苷抗病毒药物，例如阿昔洛韦、泛昔洛韦和伐昔洛韦。然而，目前的药物对潜伏性和耐药性 HSV 感染无效。一系列脒基脲化合物被设计为抗病毒药物吗啉胍的类似物，已被合成并评估为潜在的非核苷抗 HSV 药物。三种化合物显示出针对 HSV-1 的微摩尔活性和低细胞毒性，成为未来优化的有希望的候选者。初步的作用模式研究表明，新化合物在 HSV 复制周期的早期阶段起作用，就在病毒附着和感染进入阶段之后。